Contents

Highlights of This Issue  4683

SPECIAL FEATURES

CCR Translations

4685  Location, Location, Location—Makes All the Difference for Hypoxia in Lung Tumors
      Amit Maity and Constantinos Koumenis
See article p. 4843

CCR New Strategies

4688  New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers
      Augusto Villanueva, Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Helena Cornella, and Josep M. Llovet

Molecular Pathways

4695  Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
      Luca Gattinoni, Yun Ji, and Nicholas P. Restifo

Review

4702  Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
      Carey K. Anders, Eric P. Winer, James M. Ford, Rebecca Dent, Daniel P. Silver, George W. Sledge, and Lisa A. Carey

HUMAN CANCER BIOLOGY

4711  Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin’s Lymphoma via DR7 Oncoprotein
      Aurélie Lacroix, Sophie Collot-Texeira, Laurent Mardivirin, Arnaud Jaccard, Barbara Petit, Christophe Piguet, Franck Sturz, Pierre-Marie Preux, Dominique Bordessoule, and Sylvie Ranger-Rogez

4722  Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Cysticity, and Clinicopathologic Significance
      Yoshitsugu Mitani, Jie Li, Pulivarthi H. Rao, Yi-Jue Zhao, Diana Bell, Scott M. Lippman, Randal S. Weber, Carlos Caulin, and Adel K. El-Naggar

4732  Hypoxia Inducible Factor 1α and Hypoxia Inducible Factor 2α Play Distinct and Functionally Overlapping Roles in Oral Squamous Cell Carcinoma
      Gui-quan Zhu, Ya-ling Tang, Ling Li, Min Zheng, Jian Jiang, Xiao-yu Li, Si-xiu Chen, and Xin-hua Liang

CANCER THERAPY: PRECLINICAL

4742  Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells
      Rekha Rao, Srilatha Nalluri, Warren Fiskus, Andrew Savoie, Kathleen M. Buckley, Kyungsoo Ha, Ramesh Balusu, Atul Joshi, Veena Coothankandaswamy, Jianguo Tao, Eduardo Sotomayor, Peter Atadja, and Kapil N. Bhalla

4755  Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata
      Shuo Yang, Andrew M. Evens, Sheila Prachand, Amareshwar T.K. Singh, Savita Bhalla, Kevin David, and Leo I. Gordon
IMAGING, DIAGNOSIS, PROGNOSIS

4769
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

4779
Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer
Byoung Heon Kang, Markus D. Siegelin, Janet Plescia, Christopher M. Raskett, David S. Garlick, Takehiko Dohi, Jane B. Lian, Gary S. Stein, Lucia R. Languino, and Dario C. Altieri

4789
Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting
Cynthia S. Lancaster, Chaoxin Hu, Ryan M. Franke, Kelly K. Filipiski, Shelley J. Orvick, Zhaoyuan Chen, Zhili Zuo, Walter J. Loos, and Alex Sparreboom

4800
Superior Efficacy of Tumor Cell Vaccines Grown in Physiologic Oxygen
Michael R. Olin, Brian M. Andersen, David M. Zellmer, Patrick T. Grogan, Flavia E. Popsescu, Zhengming Xiong, Colleen L. Forster, Charlie Seiler, Karen S. SantaCruz, Wei Chen, Bruce R. Blazar, and John R. Ohlfest

4809
Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor
Fabio Pastorino, Monica Loi, Puja Sapra, Pamela Becherini, Michele Cilli, Laura Emionite, Domenico Ribatti, Lee M. Greenberger, Ivan D. Horak, and Mirco Ponzoni

4822
Detailed Distribution of NK012, an SN−38–Incorporating Micelle, in the Liver and Its Potent Antitumor Effects in Mice Bearing Liver Metastases
Amane Takahashi, Nobuhiro Ohkohchi, Masahiro Yasunaga, Jun-ichiro Kuroda, Yoshikatsu Koga, Hirotsugu Kenmotsu, Taira Kinoshita, and Yasuhiro Matsumura

4832
Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

4843
Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics
Edward E. Graves, Marta Vilalta, Ivana K. Cecic, Janine T. Erler, Phuoc T. Tran, Dean Felsher, Leanne Sayles, Alejandro Sweet-Cordero, Quynh-Thu Le, and Amato J. Giaccia

See commentary p. 4685

4853
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, and Ronald M. Bukowski

4864
Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types
Matthew D. Wilkerson, Xiaoying Yin, Katherine A. Hoadley, Yufeng Liu, Michele C. Hayward, Christopher R. Cabanski, Kenneth Muldrew, C. Ryan Miller, Scott H. Randell, Mark A. Socinski, Alden M. Parsons, William K. Funkhouser, Philip S. Bernard, Charles M. Perou, and D. Neil Hayes

CANCER THERAPY: CLINICAL

4876
Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
José Baselga, Andres Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, Paul Hamberg, Esther Casado, Paul Elvin, Alan Swaisland, Renee Iacona, and Josep Tabernero
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
Jenny J. Hong, Steven A. Rosenberg, Mark E. Dudley, James C. Yang, Donald E. White, John A. Butman, and Richard M. Sherry

Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer
Jonathan A. Ledermann, Hani Gabra, Gordon C. Jayson, Victoria J. Spanswick, Gordon J.S. Rustin, Mark Jitlal, Lindsay E. James, and John A. Hartley

ABOUT THE COVER
Preclinical toxicology analysis of Gamitrinibs. Animals carrying prostate cancer xenografts and treated systemically with vehicle or Gamitrinib-TPP (G-TPP) were sacrificed at the end of treatment and organs were collected and analyzed histologically. A representative image of spleen from the vehicle group is shown. For further details, please see the article by Kang and colleagues on page 4779 of this issue.
Clinical Cancer Research

16 (19)


Updated version
Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/16/19

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.